EUVIMEDEUVIMED entdecken
Crossref

Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study

Jairo Izidro Rossetti Navarro Júnior, Rafaela Aires, Thiago Antonio de Sousa Cutrim, Elisardo Corral Vasquez, Thiago Melo Costa Pereira, Bianca Prandi Campagnaro

Pharmacological Reports · 2025

DOI: 10.1007/s43440-024-00690-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Jairo Izidro Rossetti Navarro Júnior und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Physiology and Pharmacology, Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), R Mercurio s/n, Vila …. Hauptthemen laut MEDLINE: Probiotics, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa e Inovação do Espírito Santo, Fundação de Amparo à Pesquisa e Inovação do Espírito Santo, Brasil.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The therapeutic targeting of the intestinal microbiota has gained increasing attention as a promising avenue for addressing mood disorders. This study aimed to assess the potential effect of supplementing standard pharmacological treatment with the probiotic kefir in patients with Major Depressive Disorder (MDD). METHODS: Thirty-eight female participants diagnosed with moderate MDD by the Hamilton Rating Scale for Depression (HAM-D) were selected to receive the probiotic kefir in conjunction with antidepressant therapy for 12 weeks. The participants were evaluated at baseline (T0) and 90 days after probiotic kefir supplementation (T90). HAM-D scores and blood samples were collected at both time points. RESULTS: Probiotic supplementation significantly reduced MDD severity, as evidenced by lower HAM-D scores compared to baseline. Probiotic consumption for 90 days also significantly decreased interleukin-6 (IL-6), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) levels compared to baseline. However, probiotic kefir supplementation did not significantly affect serum serotonin levels. Additionally, after 90 days of probiotic consumption, insulin and morning cortisol levels were significantly reduced. In contrast, no significant changes were observed in serum levels of prolactin, vitamin D, and afternoon cortisol. CONCLUSION: This study provides valuable insights into the potential benefits of probiotics, specifically kefir, as adjunctive therapy for female patients with MDD. The findings highlight promising results in ameliorating depressive symptoms and modulating inflammatory and hormonal markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsMajor Depressive DisorderAntidepressive AgentsHumansFemaleAdultMiddle AgedTreatment OutcomeC-Reactive ProteinHydrocortisoneSerotoninInterleukin-6Psychiatric Status Rating ScalesBlood Sedimentation

Stichwörter der Autor:innen

DepressionHAM-DInflammationProbioticWomen

Substanzen

Antidepressive AgentsC-Reactive ProteinHydrocortisoneSerotoninInterleukin-6

Autor:innen und Institutionen

  • Laboratory of Translational Physiology and Pharmacology, Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), R Mercurio s/n, Vila Velha, ES, 29102623, Brazil.
  • Federal Institute of Education, Science and Technology (IFES), Vila Velha, ES, Brazil.
  • Laboratory of Translational Physiology and Pharmacology, Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), R Mercurio s/n, Vila Velha, ES, 29102623, Brazil. bianca.campagnaro@uvv.br.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa e Inovação do Espírito Santo
  • Fundação de Amparo à Pesquisa e Inovação do Espírito Santo, Brasil

Zitieren

APA

Júnior, J. I. R. N., Aires, R., de Sousa Cutrim, T. A., Vasquez, E. C., Pereira, T. M. C., & Campagnaro, B. P. (2025). Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00690-6

Vancouver

Júnior JIRN, Aires R, de Sousa Cutrim TA, Vasquez EC, Pereira TMC, Campagnaro BP. Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study. Pharmacological Reports. 2025. doi:10.1007/s43440-024-00690-6

BibTeX
@article{Jnior2025,
  author = {Júnior, Jairo Izidro Rossetti Navarro and Aires, Rafaela and de Sousa Cutrim, Thiago Antonio and Vasquez, Elisardo Corral and Pereira, Thiago Melo Costa and Campagnaro, Bianca Prandi},
  title = {Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study},
  journal = {Pharmacological Reports},
  year = {2025},
  doi = {10.1007/s43440-024-00690-6}
}
Kostenlos starten →